Medicine and Dentistry
Cerebral Hemorrhage
100%
Clinical Trial
68%
Blood Clot Lysis
54%
Alteplase
53%
Bleeding
52%
Evacuation
40%
Minimally Invasive Surgery
39%
Placebo
24%
COVID-19
23%
Infection
19%
Outpatient
14%
Convalescence
14%
Apoplexy
14%
Biological Marker
13%
Hypothermia
12%
Hematoma
12%
Adverse Event
12%
Computer Assisted Tomography
11%
Modified Rankin Scale
11%
Cavernous Hemangioma
11%
Aneurysm Surgery
11%
Randomized Controlled Trial
11%
Symptom
10%
Subarachnoid Hemorrhage
10%
Congenital Malformation
9%
Brain Artery Aneurysm
9%
Edema
9%
Quantitative Susceptibility Mapping
8%
Thrombolytic Drug
8%
Medical Care
7%
Surgeon
7%
Low Drug Dose
6%
Sodium Chloride
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Odds Ratio
6%
Clinical Research
6%
Keyphrases
Intraventricular Hemorrhage
40%
Convalescent Plasma
28%
Clot Lysis
25%
Intracerebral Hemorrhage
22%
COVID-19
20%
Clinical Trials
17%
Symptomatic Hemorrhage
16%
Trial Readiness
14%
Thrombolysis
13%
Evacuation
12%
COVID-19 Convalescent Plasma
12%
Minimally Invasive Surgery
11%
Alteplase
11%
Modified Rankin Scale
11%
Cavernous Malformation
10%
Placebo-controlled
10%
External Ventricular Drain
10%
Bleeding
10%
Hemorrhage Volume
9%
Trial Innovation Network
9%
Cerebral Aneurysm Surgery
9%
Adverse Events
9%
Spontaneous Intracerebral Hemorrhage
9%
Recombinant Tissue Plasminogen Activator (rt-PA)
9%
Hospitalization
8%
Quantitative Susceptibility Mapping
8%
Antibody Level
8%
Phase II Trial
8%
Rebleeding
7%
Clinical Outcomes
7%
Transfusion
7%
Placebo
7%
MISTIE
6%
Virus-neutralizing Antibody
6%
Catheter
6%
Inflammation
5%
Functional Benefit
5%
Lysis Rate
5%
Brain Hemorrhage
5%
Non-traumatic
5%
Randomized Trial
5%
COVID-19 Pandemic
5%
Functional Outcome
5%
